Supernus Pharmaceuticals SUPN GOCOVRI — Total revenues

Other product segments

Similar metrics at other companies

SNDAResident revenue — Total revenues

$108.43M+36.8%

ASSTOther revenue — Total revenues

$43K+514%

ALN

ALNYRoyalty revenue — Total revenues

$71.67M+79.3%

HContra revenue — Total revenues

-$17M-13.3%

FTAIMaintenance revenue — Total revenues

$30.6M-38.3%

FTAIOther revenue — Total revenues

$6.21M+19,923%

FAQ

What is Supernus Pharmaceuticals's GOCOVRI — total revenues?

Supernus Pharmaceuticals (SUPN) reported GOCOVRI — total revenues of $35.24M in Q1 2026.

How has Supernus Pharmaceuticals's GOCOVRI — total revenues changed year-over-year?

Supernus Pharmaceuticals's GOCOVRI — total revenues increased by 14.8% year-over-year, from $30.69M to $35.24M.

What is the long-term trend for Supernus Pharmaceuticals's GOCOVRI — total revenues?

Over 4 years (2021 to 2025), Supernus Pharmaceuticals's GOCOVRI — total revenues has grown at a 96.9% compound annual growth rate (CAGR), from $9.78M to $146.82M.

What does GOCOVRI — total revenues mean?

This metric represents the total gross revenue generated from the sale of a specific pharmaceutical product or therapeutic line within the company's neuroscience portfolio. It serves as a primary indicator of the product's market adoption, commercial success, and contribution to the company's overall top-line performance. Tracking this revenue stream helps investors evaluate the growth trajectory and lifecycle stage of key specialty assets.